ARC COVID-19 vaccine trial to continue on schedule

In response to recent announcements by the CDC and Pfizer that there might be a COVID-19 vaccine available by late October 2020, questions have been raised about the vaccine trial underway in Austin, conducted by Austin Regional Clinic Clinical Research. ARC has responded in a recent news report on KXAN-TV that the Pfizer COVID-19 vaccine trial will continue. Dr. Anas Daghestani, CEO of ARC has said, “Our timeline is still the same, because we have to go through a very methodical process to ensure we have the right information, we are enrolling the right patient, and we are following all the safety protocols.”

The New York Times has reported that over the past week, both Dr. Anthony S. Fauci, the country’s top infectious disease expert, and Dr. Stephen Hahn, who heads the Food and Drug Administration, have said that a vaccine may be available for certain groups before clinical trials have been completed, if the data is overwhelmingly positive. But, clinical trials will continue as scheduled.

ARC is currently in the enrollment phase of the trial which means we are calling all interested people, confirming by phone that they are qualified for the study and still interested, and booking an appointment for them to come in. We are on track to complete this phase next week, which means we will have all 250 people we need to enroll in the trial.

So far we have had over 3,500 people express interest in participating, and of the people we have spoken to, 88% are both qualified and interested to participate in the study.

Their first visit includes: informed consent (where they learn all about the study), evaluation for inclusion in the study (enrollment), exam and lab tests, Study Intervention (vaccine or placebo which is blinded), and learning all about their responsibilities for using their symptom diary and when to call us if any problems.  They're in the office over 2 hours and are free to decline participation at any point. 

Following the first visit, there is a very strict timeline to follow for the remainder of the study. That will not change.

“There’s an ongoing process whether by phone or by follow up to see if you’ve gotten exposed to the infection, did you get an infection,” explained Dr. Daghestani. ”And then we compare those who have had the vaccine to those who haven’t had the vaccine, so the study could continue for a long time.”

In the meantime, companies like Pfizer continue monitoring data from thousands of participants across the country.

“Because COVID is still active and still with us, I suspect within a month or two we could see early results of how effective it is,” said Dr. Daghestani. “Immune response to the vaccine can be determined in a few weeks.”

For more information, visit ARCclinicalresearch.com.

Tags: ARC Clinical Research, Anas Daghestani MD, COVID-19 vaccine trial

More on this Topic

ARC Clinical Research contributes to COVID-19 Vaccine Trial

ARC Clinical Research is excited to announce its participation in a prominent COVID-19 vaccine clinical trial that will begin in early August 2020.  ARC will recruit 250 ARC patients from across Central Texas to enroll in this late phase clinical trial. If you are interested in enrolling, please request to participate at ARCclinicalresearch.com or call 512-225-5931.

Austin Regional Clinic to begin COVID-19 vaccine trial

Austin Regional Clinic recently began recruiting for a COVID-19 vaccine clinical trial set to begin this month. “It is the top priority of the US and the world to find a successful vaccine to prevent the infection and spread of COVID-19,” said Dr. Gretchen Crook, principal investigator for ARC Clinical Research.

ARC Teams with Austin-based ENTvantage Diagnostics Dx for New Clinical Trial

ARC’s newest clinical trial tests a device that could help curb antibiotic overuse, "one of the most urgent threats to the public’s health,” according to the Centers for Disease Control (CDC).

ARC Begins Clinical Trials for First-of-its-Kind Device for Antibiotic Overuse

If you live in Central Texas, commonly referred to as an “allergy capital”, chances are you or a family member have suffered a sinus infection, also known as sinusitis. And chances are, if you have had sinusitis, an antibiotic has been prescribed. Yet, according to public health experts, the vast majority of sinusitis cases are not helped by antibiotics.

ARC Clinical Research Featured in Community Impact

ARC Clinical Research, based at ARC Wilson Parke, is featured in an article in Community Impact’s Lake Travis/Westlake edition. The article explains ARC’s involvement in a global study for a new antiviral flu drug, Xofluza, that may be available as early as 2019.